Jennifer Lachey - Dec 13, 2021 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Dec 13, 2021
Transactions value $
-$132,763
Form type
4
Date filed
12/15/2021, 03:48 PM
Previous filing
Nov 12, 2021
Next filing
Jan 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $575 +1.92K +2.23% $0.30* 87.6K Dec 13, 2021 Direct
transaction KROS Common Stock Sale -$76.1K -1.52K -1.73% $50.11 86.1K Dec 13, 2021 Direct F1, F2
transaction KROS Common Stock Sale -$20.4K -390 -0.45% $52.22 85.7K Dec 13, 2021 Direct F1, F3
transaction KROS Common Stock Sale -$375 -7 -0.01% $53.64 85.7K Dec 13, 2021 Direct F1
transaction KROS Common Stock Options Exercise $221 +735 +0.86% $0.30* 86.4K Dec 15, 2021 Direct
transaction KROS Common Stock Sale -$36.8K -735 -0.85% $50.00 85.7K Dec 15, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -1.92K -1.96% $0.00 96K Dec 13, 2021 Common Stock 1.92K $0.30 Direct F4
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -735 -0.77% $0.00 95.3K Dec 15, 2021 Common Stock 735 $0.30 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.495 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.06 to $52.86 inclusive.
F4 Immediately exercisable.